Skip to main content

This job has expired

You will need to login before you can apply for a job.

Vice President of Immunology, Research and Development

Employer
Molecular Templates, Inc.
Location
Austin, TX, USA
Start date
Oct 24, 2020

View more

Discipline
Regulatory, Science/R&D, Immunology
Required Education
Doctorate/PHD/MD
Position Type
Full time

Job Details

Molecular Templates, Inc. is a biopharmaceutical company developing engineered toxin bodies (ETBs), protein therapeutics with unique biologic activity for the treatment of cancer. Molecular Templates has three compounds in the clinic and has two on-going research collaborations with large pharma partners. Molecular Templates has recently demonstrated that ETBs can be used to alter the immunophenotype of tumor cells through the delivery of foreign class I antigens to intracellular compartments of tumor cells for presentation on the cell surface in complex with MHC class I (antigen seeding). Learn more at www.mtem.com.

Location: Austin, Texas or New York, NY

Position Overview

Molecular Templates is seeking an accomplished and highly-motivated individual to lead MTEMs immunology team. The VP of Immunology will be responsible for overseeing the development of MTEMs Immuno-oncology platform and programs, including the strategic leadership of projects and programs from target identification through clinical development and support of global cross-functional product teams. In addition, the VP of Immunology will be responsible for management and development of the Immunology team to support current and future R&D goals.

Responsibilities:
  • Support R&D strategic planning and contribute to high level decisions through collaboration with R&D leadership team
  • Lead preclinical immuno-oncology programs research programs and work collaboratively with product teams as candidates enter and move through clinical trials
  • Support the development of in vitro and in vivo models to characterize antigen seeding and other immunological effects with ETBs
  • Work cross-functionally to design and initiate in vivo safety and efficacy studies
  • Manage direct reports to successfully deliver on R&D goals
  • Develop and grow the immunology team as needed to support current and future R&D efforts
  • Present data at project team meetings, partner meetings, and internal reviews

Requirements:
  • Ph.D. and a minimum of eight years of industry experience in oncology drug discovery with a core focus on tumor immunology
  • Ph.D. in immunology, cell biology, molecular biology, biochemistry, or related field
  • At least eight years of relevant industry experience in in oncology drug discovery with a core focus on tumor immunology
  • Ability to work independently and also as part of a cross-functional matrixed team is expected
  • Experience leading projects and working with cross-functional teams is desired
  • Must have outstanding communication (oral and written) and presentation skills; will have opportunity to present project updates to Senior Management, partners, and scientific peers
  • Supervisory experience required
  • Demonstrated track record of independent critical thinking and scientific achievement in oncology is required

Personal Characteristics:
  • Energetic, resourceful self-starter with high integrity
  • Team-player comfortable in fast-moving, dynamic environments
  • Problem-solving orientation
  • Excellent leadership and influencing skills

Reporting Structure:

This position has supervisory responsibilities. This position reports to the Chief Scientific Officer

Molecular Templates, Inc. is an Equal Opportunity Employer and offers competitive salaries and benefits.

Molecular Templates Inc https://mtem.isolvedhire.com

Company

Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development.  Additional information about MTEM can be obtained at www.mtem.com.  

OWNERSHIP: Public

STOCK SYMBOL: MTEM

STOCK EXCHANGE: NASDAQ

Company info
Website
Phone
512-869-1555
Location
9301 Amberglen Blvd, Ste 100
Austin
TX
78729
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert